Myriad Genetics (MYGN) Misses Q3 EPS by 13c, Updates Guidance

November 1, 2022 9:06 AM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.19), $0.13 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $156.4 million versus the consensus estimate of $170.58 million.


Myriad Genetics sees FY2022 EPS of ($0.35)-($0.30), versus the consensus of ($0.06). Myriad Genetics sees FY2022 revenue of $668-672 million, versus the consensus of $692.2 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities